Sarepta Therapeutics Quietly Buys Eisai Company, Ltd.'s Vacant R&D Lab In Cambridge For $25 Million
Sarepta may be hiring, but others are hiring too! Check it out! (Isn't it tempting?)
A Cambridge pharmaceutical company, which makes a drug that treats muscular dystrophy in young boys, recently announced it is buying the vacant Eisai research lab at 100 Federal St. in a deal worth $25 million.
Sarepta Therapeutic’s purchase of the facility, which was built in 1996 and upgraded in 2006 by Japan-based cancer-research company Eisai, should be finalized by next week.
Last November, Eisai announced layoffs of 72 employees from its Federal Street facility, part of a larger, company-wide layoff.
Help employers find you! Check out all the jobs and post your resume.
A Cambridge pharmaceutical company, which makes a drug that treats muscular dystrophy in young boys, recently announced it is buying the vacant Eisai research lab at 100 Federal St. in a deal worth $25 million.
Sarepta Therapeutic’s purchase of the facility, which was built in 1996 and upgraded in 2006 by Japan-based cancer-research company Eisai, should be finalized by next week.
Last November, Eisai announced layoffs of 72 employees from its Federal Street facility, part of a larger, company-wide layoff.
Help employers find you! Check out all the jobs and post your resume.